We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Quotient Clinical Expands its Data Sciences Capabilities
Product News

Quotient Clinical Expands its Data Sciences Capabilities

Quotient Clinical Expands its Data Sciences Capabilities
Product News

Quotient Clinical Expands its Data Sciences Capabilities


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Quotient Clinical Expands its Data Sciences Capabilities"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Quotient Clinical has expanded its data sciences services in response to increasing customer demand, doubling the footprint of its facilities in Edinburgh and Nottingham, as well as increasing its specialist headcount and appointing a new Vice President.

Data sciences is an integral part of the company’s service, delivering real-time data to customers for review and interpretation, enabling crucial dosing decisions to be made during the course of a study.

Greg Johnson, the new Vice President of Data Sciences, joined Quotient in March 2015 and has over 25 years’ industry experience of directing biometrics and data sciences in large contract research organizations.

Mark Egerton, CEO of Quotient Clinical said: “Greg brings a wealth of industry experience that will be invaluable as we grow our data sciences offering. Demand for these services is rapidly increasing, and we are now undertaking electronic data capture, data management, pharmacokinetics, modeling and simulation, biostatistics and reporting on over 80% of our customer programs, compared to just 50% a few years ago.”

Greg Johnson, the new Vice President of Data Sciences, added: “Translational Pharmaceutics can have a profound impact on reducing development timelines and associated costs, and this is driving an increase in demand for all our services. I look forward to leading the growth of our data sciences capabilities, ensuring that we deliver integrated solutions for our customers.”

Advertisement